Antibody-light fusion products for cancer therapeutics
AssigneeThe University of Chicago
InventorYang-Xin Fu
Life of this patent
Estimating the term…
Abstract
Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.
Claims8
A method of reducing the growth of a primary tumor or cancer metastasis in a subject in need thereof, the method comprising:
- (a) administering to the subject a composition comprising a tumor specific antibody linked to a fragment of a human LIGHT protein to the subject, wherein the LIGHT fragment is resistant to protease digestion and is sufficient to stimulate tumor specific cytotoxic T lymphocytes against the tumor cells;
- (b) delivering a nucleic acid molecule encoding LIGHT or a fragment thereof to the primary tumor;
- and
- (c) stimulating the tumor-specific cytotoxic T-lymphocytes against the tumor or its metastases to reduce to the growth of the primary tumor or cancer metastasis.
A method of reducing the growth of a primary tumor or cancer metastasis in a subject in need thereof, the method comprising:
- (a) administering to the subject a pharmaceutical composition comprising a tumor-specific antibody;
- (b) delivering a nucleic acid molecule encoding a LIGHT protein or a fragment thereof to the tumor, wherein the LIGHT is protease resistant;
- (c) expressing the LIGHT protein or a fragment thereof stably on the surface of the tumor;
- and
- (d) stimulating activation of tumor-specific cytotoxic T-lymphocytes against the tumor to reduce the growth of the tumor or cancer metastasis.
A method of reducing the growth of a primary tumor or cancer metastasis in a subject in need thereof, the method comprising:
- (a) administering to the subject a pharmaceutical composition comprising a tumor-specific antibody;
- (b) delivering a nucleic acid molecule encoding a protease resistant LIGHT or a fragment thereof to the primary tumor;
- and
- (c) stimulating activation of tumor-specific cytotoxic T-lymphocytes against the tumor to reduce the growth of the tumor and cancer metastasis.
A method of reducing the growth of a primary tumor or cancer metastasis in a subject in need thereof, the method comprising:
- (a) administering to the subject a composition comprising a tumor specific antibody linked to a fragment of a human LIGHT protein, wherein the LIGHT fragment is resistant to protease digestion and is sufficient to stimulate cytotoxic T lymphocytes against the tumor;
- (b) delivering a nucleic acid molecule encoding a LIGHT protein or a fragment thereof to the tumor, wherein the LIGHT is protease resistant;
- (c) expressing the LIGHT protein or a fragment thereof stably on the surface of the tumor;
- and
- (d) stimulating activation of tumor-specific cytotoxic T-lymphocytes against the tumor or metastatic cells to reduce the growth of the tumor or cancer metastasis.
Dependencies are inferred from the claim text.